MedImmune Ventures appoints Ron Laufer

pharmafile | June 18, 2010 | Appointment | Research and Development |  AstraZeneca, MedImmune, appointment, research and development 

Ron Laufer has joined MedImmune’s venture capital arm as senior managing director.

The company, which is the worldwide biologics unit for AstraZeneca, said Laufer wold strengthen its long-term commitment to supporting scientific innovation through strategic venture capital investments.

“I am delighted to join MedImmune Ventures at this exciting time in biopharmaceutical research,” said Laufer. “I look forward to building on a successful history and supporting promising products and companies as they pursue our shared commitment to improving patient health.”

Advertisement

Laufer has more than 15 years industry experience, during which he co-founded Lilly Ventures, Eli Lilly and Company’s corporate venture capital fund.

He was also a managing director for healthcare-focused investment firm Visium Asset Management.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

The Gateway to Local Adoption Series

Latest content